The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Investing.com -- Shares of Regenxbio Inc . (NASDAQ: RGNX) climbed 7.2% in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) has accepted for priority review its ...

The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse events included the death of adults aged 62 and 89 years. However, the exact ...

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing ...

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...